On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Launch of New Website and Resources

  • Tryp Therapeutics recently launched a new website with updated resources to be featured on the site
  • Over the next few weeks, the company will share key resources that will be the standout features of the new website
  • Tryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities to existing investors and bring in more individuals who share in its course

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has, since its inception, led the next wave of psychedelic drug development beyond mental health. Its focus on areas of high unmet medical needs and bring relief to millions of people worldwide who are dealing with conditions such as fibromyalgia, CRPS, and Phantom Limb Pain but lack proper treatment for their conditions.

In a move that demonstrates its commitment to taking its operations further and having even a broader market reach, Tryp recently updated its website in an act to better represent the company’s current stage of development. Additionally, it plans to distribute critical resources that will be featured on its updated site, and which will act as a tool for the investment community.

Some of these resources will include an Investor Pack that will cover Tryp’s pitch deck, a factsheet, and a Frequently Asked Questions (“FAQ”) section. There will also be a dedicated FAQ for patients, coupled with a series of short QA videos from the management team. 

The updated website will also feature market opportunity info, along with QA with two key individuals. One will be Dr. Jennifer Miller, the Principal Investigator for a clinical trial to treat symptoms associated with eating disorders (https://nnw.fm/APZZx), and the other will be Kevin Boehnke, the Principal Investigator for Phase 2a clinical trial on the treatment of fibromyalgia (https://nnw.fm/PGXVN).

Tryp believes that making these critical resources assessable on the website will present more diligence opportunities to patients suffering from their targeted indications and existing investors. It also believes that by doing so, it will bring in more individuals who will share in its course, allowing them to be part of a movement dedicated to improving millions of lives around the world (https://nnw.fm/rwk98).

Over the next few weeks, the company provide updates regarding essential resources that will be the standout features of the new website. This is happening in tandem with ushering a new era for psilocybin, with Tryp’s commitment to revolutionizing what psilocybin-based treatments can do with leading-edge therapies for chronic pain and other indications.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://nnw.fm/TRYPF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217